Homepage

APSIS Therapeutics (part of GeneLancet) is a biopharmaceutical company developing novel molecules for treatment of chronic/relapsing infectious diseases. Our goal is to better people’s lives by developing first or better therapeutic solutions for unmet human medical needs.

APSIS small molecule drug discovery programs are based on our growing libraries of modified nucleosides and nucleotides, and our new prodrug technology for better drug efficacy, low toxicity, and cell specific delivery. APSIS owns proprietary bcProtide^TM prodrug technology ensuring that the active agent is being efficiently generated within the diseased cells (tumors and infected cells) from its prodrugs.

APSIS owns proprietary xelo nucleic acid-protein gene cleaving complexes and conjugates (Cas9-lgRNA^TM) technology targeting viral DNAs for curing latent, chronic and relapsing viral infections.

“To Better Lives with our Sciences”

APSIS Therapeutics, INC.

(part of GeneLancet)

Doylestown, PA 18902

E-mail: info@apsisglobal.com

http://www.apsisglobal.com